Growth hormone deficiency, acromegaly and COVID-19: Transitioning from media reports to knowledge and a growth hormone hypothesis.
作者信息
Yuen Kevin C J
机构信息
Department of Neuroendocrinology and Neurosurgery, Barrow Neurological Institute, University of Arizona College of Medicine and Creighton School of Medicine, Phoenix, AZ 85013, United States.
出版信息
Growth Horm IGF Res. 2021 Feb;56:101363. doi: 10.1016/j.ghir.2020.101363. Epub 2020 Nov 13.
Abstract
摘要
相似文献
1
Growth hormone deficiency, acromegaly and COVID-19: Transitioning from media reports to knowledge and a growth hormone hypothesis.生长激素缺乏症、肢端肥大症与2019冠状病毒病：从媒体报道到知识及生长激素假说的转变
Growth Horm IGF Res. 2021 Feb;56:101363. doi: 10.1016/j.ghir.2020.101363. Epub 2020 Nov 13.
2
Growth hormone deficiency in treated acromegaly.生长激素缺乏症在治疗后的肢端肥大症中。
Trends Endocrinol Metab. 2015 Jan;26(1):11-21. doi: 10.1016/j.tem.2014.10.005. Epub 2014 Nov 27.
3
Effects of long-term growth hormone replacement in adults with growth hormone deficiency following cure of acromegaly: a KIMS analysis.肢端肥大症治愈后生长激素缺乏的成年患者长期生长激素替代治疗的效果：一项国际多中心生长激素治疗登记研究（KIMS）分析
J Clin Endocrinol Metab. 2014 Jun;99(6):2018-29. doi: 10.1210/jc.2014-1013. Epub 2014 Apr 2.
4
Growth hormone therapy at the time of Covid-19 pandemic: adherence and drug supply issues.2019冠状病毒病大流行期间的生长激素治疗：依从性和药物供应问题。
Eur J Endocrinol. 2020 Oct;183(4):L13-L15. doi: 10.1530/EJE-20-0481.
5
Limited effects of growth hormone replacement in patients with GH deficiency during long-term cure of acromegaly.生长激素缺乏症患者在长期治疗肢端肥大症期间，生长激素替代治疗的效果有限。
Pituitary. 2009;12(4):339-46. doi: 10.1007/s11102-009-0186-y. Epub 2009 Jun 12.
6
Effect of growth hormone treatment on diastolic function in patients who have developed growth hormone deficiency after definitive treatment of acromegaly.生长激素治疗对肢端肥大症经确定性治疗后出现生长激素缺乏患者舒张功能的影响。
Growth Horm IGF Res. 2016 Feb;26:17-23. doi: 10.1016/j.ghir.2015.12.003. Epub 2015 Dec 3.
7
Fractures in pituitary adenoma patients from the Dutch National Registry of Growth Hormone Treatment in Adults.来自荷兰成人生长激素治疗国家登记处的垂体腺瘤患者骨折情况
Pituitary. 2016 Aug;19(4):381-90. doi: 10.1007/s11102-016-0716-3.
8
Acromegaly induced by growth hormone replacement therapy.生长激素替代疗法诱发的肢端肥大症。
Horm Res. 2004;61(4):165-9. doi: 10.1159/000076007. Epub 2003 Dec 31.
9
Effect of growth hormone replacement therapy on the quality of life in women with growth hormone deficiency who have a history of acromegaly versus other disorders.生长激素替代疗法对既往有肢端肥大症史与其他疾病的生长激素缺乏症女性生活质量的影响。
Endocr Pract. 2012 Mar-Apr;18(2):209-18. doi: 10.4158/EP11134.OR.
10
Evaluation of the Final Adult Height and Its Determinants in Patients with Growth Hormone Deficiency: A Single-centre Experience from the South-Eastern Region of Turkey.评估生长激素缺乏症患者的最终成人身高及其决定因素：来自土耳其东南部地区的单中心经验。
J Clin Res Pediatr Endocrinol. 2020 Sep 2;12(3):295-302. doi: 10.4274/jcrpe.galenos.2020.2019.0218. Epub 2020 Mar 11.
引用本文的文献
1
Acromegaly and COVID-19, lessons, and new opportunities.肢端肥大症与2019冠状病毒病：经验教训与新机遇
Pituitary. 2024 Dec;27(6):935-944. doi: 10.1007/s11102-024-01404-0. Epub 2024 May 31.
2
Growth hormone level in COVID-19 patients.新冠病毒肺炎患者的生长激素水平
North Clin Istanb. 2022 Oct 26;9(5):470-475. doi: 10.14744/nci.2021.90094. eCollection 2022.
3
Can telemedicine improve adherence to medical treatment? Lessons learned from research on acromegaly conducted during COVID-19 pandemic.远程医疗能否提高医疗治疗的依从性？从 COVID-19 大流行期间开展的肢端肥大症研究中吸取的经验教训。
Arch Endocrinol Metab. 2022 Nov 17;66(6):782-783. doi: 10.20945/2359-3997000000576.
4
Pathogenic Connections in Post-COVID Conditions: What Do We Know in the Large Unknown? A Narrative Review.新冠后状况中的致病关联：在众多未知因素中我们了解到了什么？一篇叙述性综述。
Viruses. 2022 Jul 30;14(8):1686. doi: 10.3390/v14081686.
5
Covid-19 and Growth Hormone/Insulin-Like Growth Factor 1: Study in Critically and Non-Critically Ill Patients.Covid-19 与生长激素/胰岛素样生长因子 1：危重症和非危重症患者研究。
Front Endocrinol (Lausanne). 2021 Jun 16;12:644055. doi: 10.3389/fendo.2021.644055. eCollection 2021.
6
COVID-19 and the Endocrine System: A Comprehensive Review on the Theme.新型冠状病毒肺炎与内分泌系统：关于该主题的全面综述
J Clin Med. 2021 Jun 29;10(13):2920. doi: 10.3390/jcm10132920.
7
Individuals with isolated congenital GH deficiency due to a GHRH receptor gene mutation appear to cope better with SARS-CoV-2 infection than controls.由于生长激素释放激素（GHRH）受体基因突变而患有孤立性先天性生长激素缺乏症的个体，似乎比对照组更能应对新型冠状病毒2（SARS-CoV-2）感染。
Endocrine. 2021 May;72(2):349-355. doi: 10.1007/s12020-021-02728-8. Epub 2021 Apr 16.
8
Pituitary Disorders and COVID-19, Reimagining Care: The Pandemic A Year and Counting.垂体疾病与新冠疫情：重塑医疗护理，大流行已过去一年且仍在持续
Front Endocrinol (Lausanne). 2021 Mar 12;12:656025. doi: 10.3389/fendo.2021.656025. eCollection 2021.
本文引用的文献
1
Novel insights into the treatment of SARS-CoV-2 infection: An overview of current clinical trials.新型冠状病毒感染治疗的新视角：当前临床试验概述。
Int J Biol Macromol. 2020 Dec 15;165(Pt A):18-43. doi: 10.1016/j.ijbiomac.2020.09.204. Epub 2020 Sep 28.
2
Is Growth Hormone Insufficiency the Missing Link Between Obesity, Male Gender, Age, and COVID-19 Severity?肥胖、男性性别、年龄与 COVID-19 严重程度之间缺失的环节是生长激素缺乏症吗？
Obesity (Silver Spring). 2020 Nov;28(11):2038-2039. doi: 10.1002/oby.23000. Epub 2020 Sep 25.
3
COVID-19: A review of the proposed pharmacological treatments.COVID-19：拟议的药理学治疗方法综述。
Eur J Pharmacol. 2020 Nov 5;886:173451. doi: 10.1016/j.ejphar.2020.173451. Epub 2020 Aug 6.
4
Growth hormone therapy at the time of Covid-19 pandemic: adherence and drug supply issues.2019冠状病毒病大流行期间的生长激素治疗：依从性和药物供应问题。
Eur J Endocrinol. 2020 Oct;183(4):L13-L15. doi: 10.1530/EJE-20-0481.
5
Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (Covid-19).肥胖症和糖尿病是导致 2019 年冠状病毒病（COVID-19）重症的高危因素。
Diabetes Metab Res Rev. 2021 Feb;37(2):e3377. doi: 10.1002/dmrr.3377. Epub 2020 Jul 20.
6
Pituitary society guidance: pituitary disease management and patient care recommendations during the COVID-19 pandemic-an international perspective.垂体学会指导意见：COVID-19 大流行期间的垂体疾病管理和患者护理建议——国际视角。
Pituitary. 2020 Aug;23(4):327-337. doi: 10.1007/s11102-020-01059-7.
7
Gender Differences in Patients With COVID-19: Focus on Severity and Mortality.COVID-19 患者的性别差异：关注严重程度和死亡率。
Front Public Health. 2020 Apr 29;8:152. doi: 10.3389/fpubh.2020.00152. eCollection 2020.
8
ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of adrenal insufficiency.COVID-19 时期的内分泌学：肾上腺功能不全的管理。
Eur J Endocrinol. 2020 Jul;183(1):G25-G32. doi: 10.1530/EJE-20-0361.
9
Endocrinology in the time of COVID-19: Management of pituitary tumours.COVID-19 时期的内分泌学：垂体瘤的治疗。
Eur J Endocrinol. 2020 Jul;183(1):G17-G23. doi: 10.1530/EJE-20-0473.
10
Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area.在纽约市地区，5700 名因 COVID-19 住院的患者的特征、合并症和结局。
JAMA. 2020 May 26;323(20):2052-2059. doi: 10.1001/jama.2020.6775.
Zotero 插件